Assort Health Raises $120M Series C at $1.2B Valuation

Assort Health has raised a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation, vaulting the San Francisco startup into unicorn territory as it scales what it calls the largest deployment of AI agents across the healthcare patient journey.

A platform, not a point solution

What began as the first voice AI agent able to schedule a specialty appointment is now a full platform spanning scheduling, intake forms, referrals, document processing, medication refills, real-time eligibility, lab requests and payments. Assort says that expansion has been powered by more than 190 million patient interactions, 62,000 care protocols and 1.6 million decision pathways, which together form what it describes as the largest proprietary specialty dataset in healthcare. In the last 15 months, revenue has grown 20x.

Synapse and the compounding-data thesis

At the core sits Synapse, Assort's proprietary AI model, which learns the patterns of specialty workflows across every deployment and then generates the edge cases, tests and simulations each practice must handle. The result, the company argues, is a structural advantage that compounds with scale. "The value of Assort's platform compounds with every patient interaction," said Matt Murphy, a partner at Menlo Ventures who will serve as a board observer. Fellow partner JP Sanday, who is joining Assort's board, called it "a unified platform of AI agents that elevates the entire patient journey."

Where the money goes

Beyond Menlo Ventures, the round drew Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Tau Ventures, Quiet Capital and NFL legend Joe Montana, bringing Assort's total funding past $222 million. The company is using the capital to push into health-system operations, partnering with organizations such as John Muir Health as demand grows for tools that can run increasingly complex ambulatory workflows. Customers report a 5% lift in appointment volume, a 115% increase in labor capacity and a 4.3 out of 5 patient satisfaction score.

An agentic-AI funding wave

Assort's raise lands amid a surge of investment in agentic AI software, where models are moving from analysis to execution. It echoes other recent rounds chronicled on our pages, from Opal Security's push to govern AI-agent identities to Patronus AI's world-models bet on agent simulation and the heavy infrastructure spending behind Baseten's $1.5 billion inference round. With administrative overhead now costing U.S. providers an estimated $1.1 trillion a year, Assort is wagering that the front door of healthcare is where AI agents prove their worth first.

Reporting based on coverage from Assort Health, Menlo Ventures, HIT Consultant and Fierce Healthcare.